Skip to content

Net margin at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
15%+3.8pp
Amgen logo
AmgenAMGN
21%+3.6pp
Gilead Sciences logo
Gilead SciencesGILD
31%+10.2pp
Exelixis logo
ExelixisEXEL
35.1%+7.1pp
CG Oncology logo
CG OncologyCGON
-3,682.6%-1,601pp
Lantheus Holdings logo
Lantheus HoldingsLNTH
18%+0.7pp

Other financials

Income statement

See full
Revenue--100%
Operating income-$48.8M-14.7%
Net income-$45.5M-14.1%
EPS (diluted)-$0.32+11.1%

Balance sheet

See full
Cash & equivalents$160.0M+162%
Total debt$32.8M-11.3%
Total equity$391.5M+135%
Total assets$435.8M+58.9%

Cash flow

See full
Operating cash flow-$44.4M-6.4%
CapEx-$2.0K-104%
Free cash flow-$44.4M-6.3%

Valuation

See full
Market cap$4.55B+1,915%
Enterprise value$4.43B+2,204%
P/S79.9×+74.4×

Profitability

See full
Operating margin-206.2%-61.0pp
FCF margin-250.1%-49.4pp

Returns & leverage

See full
Return on equity-38.4%-10.5pp
Debt / equity0.1×-0.1×
Current ratio27.4×+21.1×

Where this comes from

Calculated from Tango Therapeutics’s reported figures.

Based on trailing twelve months.

The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tango Therapeutics's net margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tango Therapeutics's net margin?
Tango Therapeutics (TNGX) reported net margin of -188.2% in Q1 2026.
How has Tango Therapeutics's net margin changed year-over-year?
Tango Therapeutics's net margin increased by 41.7% year-over-year, from -322.7% to -188.2%.
What is the long-term trend for Tango Therapeutics's net margin?
Over 4 years (2021 to 2025), Tango Therapeutics's net margin has grown at a 0.9% compound annual growth rate (CAGR), from -157.2% to -162.9%.
What does net margin mean?
Net income as a percentage of revenue (trailing twelve months). The bottom-line profitability measure after all costs, interest, and taxes.